Kidney-targeted epoxyeicosatrienoic acid (EET) analogs

Targeting the kidneys through folic acid-cosadienoic acid analogs, the problem of CKD evolution into ESRD and cisplatin nephrotoxicity was solved, renal protection and reduced side effects were achieved, and significant therapeutic potential was demonstrated.

CN111247149BActive Publication Date: 2024-12-03MEDICAL COLLEGE OF WISCONSIN INC +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN201880068624.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-09-15
Filing Date
2018-09-14
Publication Date
2024-12-03
Estimated Expiration
2038-09-14

AI Technical Summary

Technical Problem

The prior art lacks effective pharmacological therapy to prevent or delay the evolution of chronic kidney disease (CKD) into end-stage renal disease (ESRD), and cisplatin treatment in platinum-based chemotherapy often causes severe nephrotoxicity, and lacks drugs to protect the kidneys. .

Method used

Developed folic acid-costrienoic acid (EET) analogues in folic acid-cosadiene acid (EET) targeting kidney cells by coupling with folic acid receptor ligands for the treatment and prevention of kidney diseases, including cisplatin-induced kidneys Toxicity, chemicals such as PEG-diamine linkers are used to form semi-permanent linkages to improve the targeted delivery ability of drugs.

Benefits of technology

Targeted kidney delivery was achieved, reducing renal injury caused by cisplatin, showing effective protection of the kidney at lower doses, reducing systemic side effects, and having excellent therapeutic potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111247149B_ABST
    Figure CN111247149B_ABST
Patent Text Reader

Abstract

Described herein are EET analogs coupled to folate receptor ligands and the use of such coupled EET analogs for targeted delivery of therapeutic agents to cell populations having folate receptors, wherein the folate receptor ligands include, for example, folic acid or folate analogs that are recognized and selectively bound by folate receptors and other folate binding proteins. More specifically, provided herein are EET analogs coupled to folate receptor ligands and the use of such coupled EET analogs as kidney-targeted therapeutic agents.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 62 / 559,355, filed on September 15, 2017, the entire contents of which are incorporated herein by reference.

[0003] Statement Regarding Federally Funded Research

[0004] none Background Art

[0005] According to the National Kidney Foundation, 10% of the world's population is affected by chronic kidney disease (CKD), and millions of people die each year due to a lack of access to affordable or effective treatments. As the prevalence of CKD and end-stage renal disease (ESRD) increases, the economic burden of CKD is a growing concern for patients, their caregivers, and payers. The clinical complexity of managing patients with CKD and ESRD incurs significant healthcare costs, including costs associated with the detection and management of CKD, the treatment of ESRD, and the simultaneous management of coexisting conditions such as diabetes, hypertension, and congestive heart failure. Progressive organ damage associated with renal and cardiovascular disease is a major cause of morbidity and mortality. Hypertension and diabetes are two of the main diseases that contribute to the rise in ESRD and the number of patients on dialysis. Despite the increased awareness that chronic kidney disease (CKD) has become a major medical problem worldwide, there are few pharmacological therapies available to prevent or delay the progression of CKD to end-stage renal disease (ESRD), let alone curative therapies.

[0006] Drug-induced nephrotoxicity is also a problem for patients receiving platinum-based chemotherapy for various malignancies. For example, cisplatin is an effective chemotherapeutic agent, but there are some adverse side effects associated with the use of cisplatin in clinical practice. For patients treated with cisplatin, the most common adverse reaction is severe nephrotoxicity, which occurs in 25-40% of patients treated with cisplatin. It is well known that there is a need to develop a drug that can protect the kidneys from the adverse effects of cisplatin during clinical use. BRIEF DESCRIPTION OF THE DRAWINGS

[0007] Figure 1 is a schematic diagram of the chronic study protocol.

[0008] Figure 2 The folate-conjugated form of the EET analogs was shown to target the kidney.

[0009] Figure 3 It was shown that the use of folate-conjugated EET analogs reduced cisplatin-induced renal injury.

[0010] Figure 4Embodiments of folate-conjugated EET analogs are shown. DETAILED DESCRIPTION

[0011] All publications, including but not limited to patents and patent applications, cited in the specification are herein incorporated by reference as if fully set forth in this application.

[0012] Described here and on the following pages are kidney-targeted epoxyeicosatrienoic acid (EET) analogs, and methods of using such EET analogs to treat kidney and cardiovascular diseases. More specifically, provided herein are EET analogs coupled to folate receptor ligands and the use of such coupled EET analogs as kidney-targeted therapeutic agents, wherein the folate receptor ligands are, for example, folic acid or folic acid analogs that are recognized and selectively bound by folate receptors and other folate binding proteins. In general, these compounds and methods are based at least in part on the inventors' development of EET agonists and analogs with promising therapeutic potential for cardiovascular and kidney diseases. The inventors previously synthesized a series of analogs of 14,15-EET, defined the basic pharmacophores and stabilized them to prevent metabolic inactivation. A subset of these analogs, referred to as EET-A, EET-B and EET-C22, have good pharmacokinetic properties and are orally active. See, e.g., PCT / US2012 / 032090 and U.S. Patent Nos. 9,422,318 and 9,127,027, each of which is incorporated herein by reference in its entirety.

[0013] In the first aspect, there is provided herein a kidney-targeted epoxyeicosatrienoic acid (EET) analog, comprising an EET analog coupled to a folic acid (also referred to as folate) receptor ligand (e.g., folic acid, methotrexate, or a folic acid analog bound to a folic acid receptor). Without being bound by any particular theory or mechanism of action, it is believed that the connection of a folic acid receptor ligand to an EET analog targets cells that express high levels of folate receptors (FRs), such as proximal tubular cells of the kidney. Suitable folate receptor ligands include folic acid, methotrexate, and a folic acid analog bound to a folic acid receptor. A folate receptor ligand can be directly coupled to an EET analog, or a folate receptor ligand can be indirectly coupled to an EET analog via a linker.

[0014] In some cases, the EET analog used to form the conjugated compound is selected from the group consisting of:

[0015]

[0016] In certain embodiments, compounds of the invention having the following formula also exhibit binding affinity for the folate receptor:

[0017]

[0018] Linkers and linking chemistries suitable for folic acid conjugation of EET analogs to synthesize kidney-targeted EET analogs include, but are not limited to, polyethylene glycol (PEG) linkers, PEG-diamine linkers. For example, in certain embodiments, the EET analog is conjugated to the folate receptor ligand via a PEG diamine linker. In other cases, the linker includes ethylenediamine (see, e.g., Figure 4 ), diisocyanate, diisothiocyanate, carbodiimide, bis(hydroxysuccinimide) ester, maleimide-hydroxysuccinimide ester, glutaraldehyde or a combination thereof.

[0019] The linker may create a permanent or semi-permanent (ie, unstable) linkage. The inclusion of a semi-permanent linkage is particularly advantageous for applications requiring cellular uptake of the drug.

[0020] The synthesis of kidney-targeted EET analogs can be completed according to the following exemplary synthesis scheme. The synthesis of other folic acid analogs can be completed by methods known to the skilled person. In addition, the optional incorporation of a linker can also be achieved by methods known to those skilled in the art.

[0021] Synthesis of folic acid-conjugates

[0022] Synthesis of EET-F01:

[0023]

[0024]

[0025] Experimental process:

[0026]

[0027] Add diisopropylethylamine (DIPEA, 1.18 mL, 6.78 mmol, 3.00 equiv) to N-hydroxysuccinimide (NHS) folate 1 (1) (11.44 g, 2.26 mmol) and 2-[2-(2-aminoethoxy)ethoxy]-N-tritylethane-1-amine 2 (2) (1.06 g, 2.71 mmol, 1.20 equiv) in anhydrous DMSO (20 mL). After 18 h, DMSO was evaporated (50 °C, 0.1 torr) and the residue was triturated with acetone / ether (20 / 70, 2 x 50 mL) and then acetone (2 x 50 mL). The residue was dried under high vacuum overnight to give an orange solid (orange solid, 2.00 g) which was used in the next step without further purification.

[0028]

[0029] Trifluoroacetic acid (TFA, 5.36 mL) was added dropwise to a suspension of crude 3 (1.09 g, 1.34 mmol) in CH2Cl2 / H2O (5 / 1, 6 mL). After gentle shaking for 2 hours, the mixture was concentrated in vacuo and the residue was azeotropically dried with anhydrous toluene (10 mL). The residue was triturated with CH2Cl2 (5×5 mL); the yellowish CH2Cl2 supernatant was removed with a pipette each time, with each wash causing the yellow color to gradually lighten until it was almost colorless. The crude 4 (thick red oil) was used in the next step without further purification.

[0030]

[0031] DIPEA (1.13 mL, 6.50 mmol, 5.00 equiv) was added dropwise to a suspension of crude 4 (0.891 g, 1.30 mmol) in anhydrous DMSO (6 mL). After 15 minutes, a solution of NHS EET analog ester 5 (0.569 g, 1.30 mmol) in anhydrous CH2Cl2 (6 mL) was added. After 24 hours, the reaction mixture was diluted with ice-cold 20% acetone / Et2O (50 mL). The supernatant was decanted and the residue was separated from the resulting precipitate and then triturated with additional 20% acetone / Et2O (50 mL), 50% acetone / Et2O (100 mL), 0.1 N HCl (20 mL) and acetone (2×50 mL). The residue was dried under high vacuum overnight to give EET-F01 (6) (0.690 g, 59%) as an orange solid.

[0032] 1 H NMR(500MHz,DMSO-d6)δ8.65(s,1H),7.93–7.80(m,1H),7.73–7.58(m,2H),6.95(s,1H),6.64 (dd,J=8.7,2.3Hz,2H),5.79–5.69(m,2H),5.38–5.28(m,2H),4.49(d,J=6.1Hz,2H),3.52–3. 45(m,4H),3.22–3.13(m,4H),3.01–2.87(m,4H),2.10–2.09(m,2H),2.05(t,J=7.5Hz,2H),2. 01–1.93(m,4H),1.51–1.40(m,2H),1.40–1.14(m,18H),0.86(t,J=7.0Hz,3H).LCMS(ES-APCI + )[C 44 H 67 N 11 O9] +Calculated value 894.1, measured value 894.4.

[0033] Synthesis of NHS EET analog ester 5. N-hydroxysuccinimide (NHS, 0.165 g, 1.43 mmol, 1.10 equiv) and dicyclohexylcarbodiimide (DCC, 0.322 g, 1.56 mmol, 1.20 equiv) were added to a stirred 0 °C EET analog. 3 7 (0.443 g, 1.30 mmol) in anhydrous EtOAc (26 mL). After 5 minutes, N,N-dimethylpyridine (DMAP, 15.9 mg, 0.13 mmol, 0.100 equiv) was added and the suspension was warmed to room temperature. After 24 hours, the reaction solution was passed through Celite TM Filter through a Celite pad and TM The bed was washed with EtOAc. The filtrate was washed with saturated aqueous NaHCO3 (10 mL) and brine (10 mL). The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to give crude 5, which was used in the next step without further purification.

[0034] Synthesis of EET-A folic acid conjugate:

[0035]

[0036] Synthesis 9. EEE-A disodium salt 3 A mixture of 2-(1-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2- R f The crude product was purified by chromatography system (4 g SiO2 column) eluting with a gradient of 0-100% EtOAc / hexanes over 25 min; 100% EtOAc over 15 min; and 10% MeOH / CH2Cl2 over 7 min to afford 9 (169 mg, 70%).

[0037] 1H NMR (500MHz, CD3OD) δ7.51–7.44(m,14H),7.33–7.25(m,14H),7.24–7.17(m,6H),5.87(s,1H),5. 40–5.33(m,2H),4.69(dd,J=7.5,5.9Hz,1H),3.71–3.49(m,18H),3.17–3.07(m,4H),2.62(dd,J= 15.0,6.0Hz,1H),2.53(dd,J=15.0,7.7Hz,1H),2.35(t,J=5.5Hz,4H),2.21(t,J=7.6Hz,3H),2.1 3–1.99(m,4H),1.66–1.54(m,2H),1.53–1.45(m,4H),1.43–1.26(m,14H),0.93(t,J=6.9Hz,3H).

[0038] Synthesis of 10. Trifluoroacetic acid (TFA, 0.40 mL) was added dropwise to a mixture of trityl protected amine 9 (130 mg, 0.108 mmol) in H2O (0.50 mL) and CHCl3 (1.5 mL). After 45 minutes, the reaction was diluted with MeOH (3 mL) and concentrated in vacuo. Coevaporation with toluene (3×5 mL) gave 10 as a white solid which was used in the next step without further purification.

[0039] Synthesis of 11. DIPEA (77 μL, 0.432 mmol, 4 eq) was added to a mixture of crude 1 (116 mg, 0216 mmol, 2 eq) and 10 (77 mg, 0.108 mmol) in anhydrous DMSO (1.50 mL). After 40 hours, the mixture was poured into Et2O (25 mL) at 0°C with stirring. The supernatant was carefully decanted from the resulting precipitate, and the precipitate was ground with acetone / Et2O (30 / 70, 30 mL) and acetone / CH2Cl2 (30 / 70, 30 mL). The residue was dried under high vacuum to give 11 (57 mg) as an orange solid.

[0040] 1H NMR (500MHz, DMSO-d6) δ8.73–8.61(m,2H),8.12–7.83(m,4H),7.76–7.55(m,3H),7.03–6.88(m,2H),6.64(dd,J=7.8,4.5Hz,4H),5.76(br s,2H),5.40–5.20(m,2H),4.57–4.42(m,5H),3.68–3.44(m,14H),3.22–3.08(m,6 H),3.06–2.88(m,6H),2.02–1.84(m,7H),1.53–1.14(m,18H),0.92–0.78(m,3H).

[0041] The kidney-targeted EET analogs described herein can be formulated with a pharmaceutically acceptable carrier or excipient to form a primary therapeutic agent. A "pharmaceutically acceptable carrier" is a substance that can be used as a carrier for administering a therapeutic or prophylactic agent (e.g., a kidney-targeted EET analog) because the substance is inert or medically acceptable and compatible with the therapeutic or prophylactic agent.

[0042] Also disclosed are kits comprising conjugates and / or complexes and pharmaceutically acceptable excipients to form therapeutic agents. The kit may include implementation tools for administering the therapeutic agent. In addition, the kit may include one or more supplementary therapeutic agents and / or diagnostic agents.

[0043] The beneficial properties of kidney-targeted EET analogs as described herein also include: targeted delivery of EET analogs to the kidney, thereby utilizing the useful biological properties of EETs (e.g., vasodilation, anti-inflammatory, anti-apoptotic, and anti-fibrotic) in a targeted manner; use as prophylactic agents as well as interventional therapies to prevent or limit nephrotoxicity; being effective at doses tenfold lower than untargeted EET analogs; and fewer systemic side effects.

[0044] In another aspect, provided herein is a method for treating a renal disease in a subject in need thereof with a compound as described herein. Also provided herein is a method for delivering a therapeutic agent to a target cell population comprising a folate receptor, the method comprising providing a compound as described in claim 1, and contacting the target cell population with an effective amount of the compound to allow the compound to bind to the folate receptor.

[0045] The therapeutic and preventive applications of the EET analogs for kidney targeting described herein include, but are not limited to: treatment of renal diseases starting from the proximal tubules, acute tubular necrosis (ATN) and ischemic renal injury after bypass or transplantation surgery; treatment or prevention of drug-induced nephrotoxicity, including nephrotoxicity caused by cisplatin; used as a preservative for preserving kidneys to be transplanted; treatment of diabetic nephropathy, focal segmental glomerulosclerosis (FSGS) and chronic kidney disease (CKD). Other therapeutic and preventive applications of the EET analogs for kidney targeting provided herein include: treatment and / or prevention of drug- and radiation-induced renal damage, hypertension and cardiorenal syndrome renal damage, as well as metabolic syndrome and diabetic nephropathy.

[0046] Unless otherwise defined, all technical and scientific terms used herein are consistent with the common understanding of one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used to implement or test the present invention, preferred methods and materials are described herein.

[0047] The following examples illustrate certain embodiments of the present invention. The examples, methods and conditions set forth therein should not be construed as limiting the scope or spirit of the present invention.

[0048] Example

[0049] Example 1 - Kidney-targeted delivery of EET analogs

[0050] Epoxyeicosatrienoic acid (EET) analogs have excellent therapeutic potential to combat cardiovascular and renal diseases. EET analogs can combat damage in acute and chronic kidney disease models. Due to the biological effects of EET analogs, such as vasodilation, anti-inflammatory, anti-apoptotic and anti-fibrotic, they are very suitable for the treatment of kidney diseases. Although EET analogs perform well in several in vivo models, it is reasonable to expect that targeted delivery of EET analogs to the kidney can reduce the drug levels required to achieve therapeutic effects in the kidney and eliminate possible side effects.

[0051] For kidney-targeted delivery of EET analogs, we coupled EET analogs to folic acid because the concentration of folate receptors in kidney tissue is high. EET analogs were coupled to folic acid via a PEG-diamine linker. Next, we compared the kidney-targeted EET analog EET-F01 with the well-studied EET analog EET-A. EET-A or EET-F01 was infused intravenously (10 mg / kg / hr) through the rat jugular vein for 6 hours. Plasma and kidney tissue were collected and EET-A or EET-F01 was measured by LC-MS-MS. EET-A plasma levels were 1.6 ng / mL, but EET-A was not detected in the kidneys. On the other hand, EET-F01 was 6.5 ng / mL in plasma and 26.7 ng / mL in kidney tissue. These data indicate that EET-F01 targets the kidneys. Experiments were conducted to compare the effects of EET-F01 and EET-A in reducing cisplatin-induced nephrotoxicity. A single injection of cisplatin (7 mg / kg ip) was given to WKY rats treated with vehicle, EET-A (10 mg / kg ip) or EET-F01 (20 mg / kg or 2 mg / kg ip) for 5 days. Cisplatin increased BUN (125±11 mg / dL) and NAG (12±4 IU / L) compared to controls (36±9 mg / dL and 4±1 IU / L). Five days after cisplatin administration, EET-F01 was as effective as EET-A in reducing BUN, NAG, and renal histological damage. Although the molecular weight of EET-F01 is nearly twice that of EET-A, EET-F01 can effectively reduce BUN and NAG at 20 mg / kg / d and at a 10-fold lower dose of 2 mg / kg / d. These data clearly show that EET-F01 targets the kidneys and allows for lower effective doses. In conclusion, we have developed a kidney-targeted EET analog, EET-F01, which has great potential for treating kidney diseases.

[0052] Example 2 - Prevention of cisplatin-induced nephrotoxicity using kidney-targeted EET analogs

[0053] Cisplatin is a platinum-based inorganic chemotherapeutic agent that can be used to treat a variety of malignancies (1-3). However, the use of cisplatin in clinical practice can produce some adverse side effects. Among these adverse reactions, the most common adverse reaction is severe nephrotoxicity that occurs in 25-40% of cisplatin-treated patients, which affects the effective use of this chemotherapeutic agent (4-7). It is well known that there is a need to develop a drug that can protect the kidneys from the adverse effects of cisplatin during clinical use. One approach that can be used to develop renal protective agents against cisplatin nephrotoxicity is to target the CYP cyclooxygenase pathway, which produces epoxyeicosatrienoic acid (EET) from arachidonic acid.

[0054] Several studies have shown that EETs display a variety of biological actions that can be used to protect organs, including the kidney (8,9). In these studies, we have demonstrated that synthetic EET mimetics can protect the kidney in a variety of pathological conditions, such as hypertension, cisplatin nephrotoxicity, and radiation nephropathy (10-14). These studies clearly demonstrate the potential of EET-based approaches to protect the kidney in pathological conditions of different etiologies, and we have developed several synthetic EET analogs with EET-mimetic properties.

[0055] Recently, attempts have been made to develop EET analogs with EET mimetic activity as well as the unique property of targeting the kidney. We have developed a new form of kidney-targeted EET analog by coupling the EET pharmacophore to folic acid. In preliminary studies, we investigated its ability to target the kidney compared to EET analogs without folic acid conjugation. We also compared the ability of the folic acid-conjugated EET analog to the original EET analog without any folic acid moiety in protecting the kidney from cisplatin nephrotoxicity.

[0056] Materials and methods

[0057] Unless otherwise stated, all chemicals and assay kits were purchased from Sigma Aldrich (St. Louis, MO, USA). EET analogs were designed and synthesized in the laboratory of John R. Falck, Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX.

[0058] Animal studies: All animal studies were approved and performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Medical College of Wisconsin. The animals were housed in a temperature-controlled environment with a 12-h light / dark cycle and were allowed free access to food and water. Rats were acclimated for 6 days before the experiments.

[0059] Acute study: Male SD rats (10 weeks old) fasted overnight (12-14 hours) were anesthetized with sodium pentobarbital (60 mg / kg, ip). After tracheotomy, the left jugular vein was cannulated and the vehicle or EET-A or folic acid-coupled EET analogs were continuously infused at a rate of 6 ml / kg / hr for 6 hours. Plasma and kidney samples were collected at the end of the protocol, snap-frozen in liquid nitrogen, and stored at -80°C until LC-MS analysis. EET-A and folic acid-coupled EET analog solutions were prepared in 0.1% DMSO and 1% PEG-400 in saline.

[0060] Chronic study: In the chronic study, male Wistar-Kyoto (WKY) rats weighing 180-200 g (Charles River, Massachusetts, USA) were used. The rats were divided into four groups (n=4 per group). The rats in group 1 had free access to water and were given DMSO (300-500 μl, ip) on day 7 for the preparation of a solution of cisplatin. At the same time, rats in groups 2, 3, 4, and 5 were pretreated with vehicle (20% DMSO in PEG-400 v / v), EET analogs (EET analogs in double distilled water) or the novel folate-coupled EET analog F01 at doses of 20 mg / kg and 2 mg / kg (prepared with a mixture of 20% DMSO in PEG400) for 7 days in an osmotic minipump (2ML, Alzet, Cupertino, CA). On day 7, the rats were given a single dose of cisplatin (7 mg / kg ip), followed by five days of vehicle, EET-A, and F01 treatment. One day before euthanasia, urine was collected from each rat over a 24-hour period. Five days after cisplatin or vehicle administration, the rats were anesthetized to collect blood samples and then euthanized. A schematic diagram of the protocol is shown in Figure 1 shown.

[0061] Biochemical analysis: Blood urea nitrogen (BUN) levels (BioAssay Systems, Hayward, CA, USA) and urinary N-acetyl-β-(D)-glucosaminidase (NAG) activity in urine were measured using a Diazyme kit (Diazyme Laboratories, Poway, CA, USA).

[0062] Mass spectrometry: The levels of EET-A and folate-conjugated EET-A in plasma and kidney were measured by LC–ESI–MS. Samples were prepared by solid phase extraction from 200 μl of plasma or kidney homogenate from rats treated with EET-A or folate-conjugated EET-A using a C18 column (Agilent Technologies, Santa Clara, CA, USA). The extracted samples were stored at -80 °C prior to analysis. The samples were warmed to room temperature, dried under a stream of nitrogen, and the residue was reconstituted in 20 μL of acetonitrile with a 12 μL injection volume. The components were resolved on a 250 mm x 2.0 mm Kromasil C18 column equipped with a 5 μm diameter The particles were eluted with a gradient from 80% A to 10% A at a flow rate of 0.2 mL / min. Solvent A was water with 0.01% formic acid, solvent B was acetonitrile with 0.01% formic acid, and the following process was used: 20% B to 30% B in 10 min, 30% B to 60% B in 17 min, 60% B to 90% B in 28 min, 100% hold for 7 min, and then re-equilibrate for 7 min. MS / MS analysis was performed on a Jet Stream TM The analysis was performed on an Agilent 6460 triple quadrupole mass spectrometer with an Agilent 6460 interface. Precursor ions, product ions, collision energies, and fragmentor voltages were optimized for negative polarity for each compound. Other parameters were as follows: drying gas flow = 10 L / min at 325 °C, nebulizer = 20 psi, sheath gas flow = 11 L / min at 325 °C, capillary = 3.5 kV, nozzle = 1.0 kV. Results obtained at unit mass resolution.

[0063] result

[0064] After acute intravenous administration, plasma and kidney levels of F01 were higher than those of EET-A.

[0065] In acute animal studies, equal doses of EET-A and F01 were intravenously administered for 6 hours, and then plasma and kidney tissue were collected. After continuous administration of F01 and EET-A for 6 hours, we demonstrated that the plasma level of F01 was 5-fold higher than that of EET-A ( Figure 2 Interestingly, we also demonstrated that after 6 h of continuous administration, the renal content of EET-A was almost undetectable compared with the F01 content in the kidney ( Figure 2 ).

[0066] Chronic treatment with F01 showed better renal protective effect than EET-A against cisplatin nephrotoxicity.

[0067] In another experimental group, rats were pretreated with F01 and EET-A before induction of cisplatin nephropathy and then treated with the test compounds (F01 and EET-A) for another 5 days. The renal protective effects of F01 and EET-A depended on the level of blood urea nitrogen (BUN) and the content of NAG in urine. We demonstrated that F01 had a better renal protective effect than the non-folate form of EET analog EET-A ( Figure 3 ).

[0068] in conclusion

[0069] The folate-conjugated form of the EET analog F01 has the ability to reach the plasma and kidneys faster than the non-folate-conjugated form. In addition, the F01 compound showed better renal protection than EET-A in resisting cisplatin nephrotoxicity.

[0070] References

[0071] Bongers ML, Coupé V.M., Jansma EP, Smit EF, Uyl-de Groot CA (2012) Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics 30, 17-34.

[0072] Levy AR, Johnston KM, Sambrook J., Donato B., Penrod JR, Corral M., Chasen M. (2011) Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. Curr. Med. Res. Opin. 27, 2253-2259.

[0073] Wang D., Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307-320.

[0074] Kintzel PE (2001) Anticancer drug-induced kidney disorders. Drug Saf. 24, 19-38.

[0075] Miller RP, Tadagavadi RK, Ramesh G., Reeves WB (2010) Mechanisms of Cisplatin nephrotoxicity. Toxins 2, 2490-2518.

[0076] Sánchez-González PD, López-Hernández FJ, López-Novoa JM, Morales A.I. (2011) An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit. Rev. Toxicol. 41, 803-821.

[0077] Perazella MA, Moeckel GW (2010) Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention / therapy. Semin. Nephrol. 30, 570-581.

[0078] Imig JD (2012) Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol. Rev. 92, 101-130.

[0079] Imig JD, Hammock BD (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8, 794-805.

[0080] Khan AH, Falck JR, Manthati VL, Campbell WB, Imig JD (2014) Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury. Front Pharmacol. 5, 216.

[0081] Khan MA, Liu J., Kumar G., Skapek SX, Falck JR, Imig JD (2013) Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. FASEB J. 7(8), 2946-56.

[0082] Hye Khan MA, Fish B., Wahl G., Sharma A., Falck JR, Paudyal MP, Moulder JE, Imig JD, Cohen EP (2016) Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy. Clin Sci (Lond). 30(8), 587-99.

[0083] Hye Khan MA, Neckár J., Manthati V., Errabelli R., Pavlov TS, Staruschenko A., Falck JR, Imig JD (2013) Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat. Hypertension. 62(5), 905-13.

[0084] The present invention has been described in terms of one or more preferred embodiments, but it should be understood that many equivalents, alternatives, variations and modifications besides those explicitly described are possible and within the scope of the present invention.

Claims

1. A compound having the formula:

2. A pharmaceutical composition comprising the compound according to claim 1 and at least one component selected from a pharmaceutically acceptable carrier, excipient or diluent.

3. Use of the compound as claimed in claim 1 in the preparation of a medicament for treating kidney disease.

4. Use of the compound according to claim 1 in the preparation of a medicament for reducing nephrotoxicity.

5. The use according to claim 4, wherein The nephrotoxicity was drug-induced.

6. The use according to claim 4, wherein The nephrotoxicity was caused by cisplatin.

7. Use of a compound as claimed in claim 1 in the preparation of a medicament for delivering a therapeutic agent to a target cell population comprising a folate receptor.

Citation Information

Patent Citations

  • Systems, methods, and apparatus for anode and cathode electrical separation in detectors

    US20120032090A1

  • Epoxyeicosatrienoic acid analogs and methods of making and using the same

    US9127027B2

  • Epoxyeicosatrienoic acid analogs and methods of making and using the same

    US9422318B2

  • Epoxyeicosatrienoic acid analogs and methods of making and using the same

    CN103764621A

  • Compounds for improved viral transduction

    CN103958667A